Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.56 |
| ▸ | ERN1 | O75460 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | KIF11 | P52732 | 2/20 | 0.40 |
| ▸ | F2 | P00734 | 1/20 | 0.40 |
| ▸ | F10 | P00742 | 1/20 | 0.40 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | ATR | Q13535 | 2/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5906546 | 0.85 | ERN1 (0.48) | HDAC1HDAC6ERN1ALDH1A1HPGD | |
| SCHEMBL6865515 | 0.82 | MAPT (0.48) | ERN1ALDH1A1HPGDSMN1; SMN2MAPT | |
| SCHEMBL2653855 | 0.82 | CES2 (0.59) | ERN1ALDH1A1HPGDSMN1; SMN2PDK2 | |
| SCHEMBL8280051 | 0.80 | HDAC1 (0.47) | HDAC1HDAC6PDK2CTSLCTSS | |
| SCHEMBL13205433 | 0.79 | PDK2 (0.47) | ERN1ALDH1A1HPGDSMN1; SMN2MAPT | |
| SCHEMBL1853218 | 0.79 | ALDH1A1 (0.46) | ALDH1A1HPGDSMN1; SMN2MAPTGAA | |
| SCHEMBL16905393 | 0.79 | HDAC1 (0.58) | HDAC1HDAC6ERN1ALDH1A1HPGD | |
| SCHEMBL29447970 | 0.79 | PDK2 (0.47) | ERN1ALDH1A1HPGDSMN1; SMN2MAPT | |
| SCHEMBL355413 | 0.79 | ESR1 (0.60) | ERN1ALDH1A1HPGDSMN1; SMN2PDK2 | |
| SCHEMBL384544 | 0.79 | MAPT (0.46) | ERN1ALDH1A1HPGDSMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2906559-B1 | AZAINDOLINES | HOFFMANN LA ROCHE (CH) | 2017-02-08 | — | — | EP | claimed |
| US-9309248-B2 | Azaindolines | HOFFMANN-LA ROCHE INC. (US) | 2016-04-12 | — | — | US | claimed |
| US-20150266879-A1 | AZAINDOLINES | HOFFMANN-LA ROCHE INC. | 2015-09-24 | — | — | US | claimed |
| EP-2906559-A1 | AZAINDOLINES | F. Hoffmann-La Roche AG (CH) | 2015-08-19 | — | — | EP | claimed |
| WO-2014056871-A1 | AZAINDOLINES | F. HOFFMANN-LA ROCHE AG (CH) | 2014-04-17 | — | — | WO | claimed |
| US-11724992-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NOVARTIS AG (CH) | 2023-08-15 | — | — | US | disclosed |
| US-11724992-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NOVARTIS AG (CH) | 2023-08-15 | — | — | US | disclosed |
| CN-111601807-B | Exo-azaspiro inhibitors of MENIN-MLL interactions | 詹森药业有限公司 | 2023-03-31 | — | — | CN | disclosed |
| US-20230063462-A1 | SULFONIMIDAMIDE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-03-02 | — | — | US | disclosed |
| US-20230063462-A1 | SULFONIMIDAMIDE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-03-02 | — | — | US | disclosed |
| US-20230062815-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-03-02 | — | — | US | disclosed |
| US-20230051589-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-02-16 | — | — | US | disclosed |
| EP-1671949-A2 | Substituted phenylamines and pyridinylamines | WARNER-LAMBERT COMPANY LLC (US) | 2006-06-21 | — | — | EP | disclosed |
| US-7030141-B2 | Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade | WARNER-LAMBERT COMPANY LLC | 2006-04-18 | — | — | US | disclosed |
| EP-1465864-B1 | INHIBITORS OF FACTOR XA AND OTHER SERINE PROTEASES INVOLVED IN THE COAGULATION CASCADE | WARNER LAMBERT CO (US) | 2006-03-15 | — | — | EP | disclosed |
| US-20050267118-A1 | Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade | WARNER-LAMBERT COMPANY LLC | 2005-12-01 | — | — | US | disclosed |
| US-20050250815-A1 | Inhibitors of fractor Xa and other serine proteases involved in the coagulation cascade | WARNER-LAMBERT COMPANY LLC | 2005-11-10 | — | — | US | disclosed |
| EP-1465864-A1 | INHIBITORS OF FACTOR XA AND OTHER SERINE PROTEASES INVOLVED IN THE COAGULATION CASCADE | Warner-Lambert Company LLC (US) | 2004-10-13 | — | — | EP | disclosed |
| US-20030162787-A1 | Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade | WARNER-LAMBERT COMPANY LLC | 2003-08-28 | — | — | US | disclosed |
| WO-2003045912-A1 | INHIBITORS OF FACTOR XA AND OTHER SERINE PROTEASES INVOLVED IN THE COAGULATION CASCADE | WARNER-LAMBERT COMPANY LLC (US) | 2003-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230062815-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | HDAC1 575/4885HDAC6 569/4885ERN1 2078/4885 |
| US-20150266879-A1 | AZAINDOLINES | AZI2, H1-5, CCNY | HDAC1 16/4885HDAC6 100/4885ERN1 3823/4885 |
| US-20230051589-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | HDAC1 596/4885HDAC6 624/4885ERN1 1882/4885 |
| US-20050267118-A1 | Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade | F12, TFPI, F11 | HDAC1 1151/4885HDAC6 2460/4885ERN1 889/4885 |
| US-20030162787-A1 | Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade | TFPI, F11, F12 | HDAC1 951/4885HDAC6 2757/4885ERN1 472/4885 |
| US-20230063462-A1 | SULFONIMIDAMIDE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | HDAC1 363/4885HDAC6 491/4885ERN1 1953/4885 |
| US-11724992-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NLRP1, NLRP3, NOD1 | HDAC1 575/4885HDAC6 569/4885ERN1 2078/4885 |
| US-20050250815-A1 | Inhibitors of fractor Xa and other serine proteases involved in the coagulation cascade | F12, TFPI, F11 | HDAC1 1283/4885HDAC6 2196/4885ERN1 796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.